Hutchison China MediTech (688136.SH): Innovative drug GB18 injection granted US FDA approval for new drug clinical trials.

Smart Finance News, Ke Xing Pharmaceuticals (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Ke Xing Pharmaceutical Co., Ltd. (referred to as "Shenzhen Ke Xing" below), has received notification from the U.S. Food and Drug Administration (referred to as "FDA" below) that the clinical trial application for the innovative drug GB18 Injection developed independently by Shenzhen Ke Xing has been approved by FDA and can be conducted in the United States. The indication is for the treatment of cancer cachexia.